- Cost-effectiveness of chronic hepatitis C screening and treatment
-
Lee HW, Lee H, Kim BK, Chang Y, Jang JY, Kim DY
- KMID: 2528244
- Clin Mol Hepatol.
- 2022 Apr;28(2):164-173.
- doi: 10.3350/cmh.2021.0193
Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence... -
- CITED
-
- Close
- SHARE
-
- Close
- A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
-
Kim HL, Kim KA, Choi GH, Jang ES, Ki M, Choi HY, Jeong SH
- KMID: 2523874
- Clin Mol Hepatol.
- 2022 Jan;28(1):91-104.
- doi: 10.3350/cmh.2021.0236
Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
-
Heo J, Kim YJ, Lee JW, Kim JH, Lim YS, Han KH, Jeong SH, Cho M, Yoon KT, Bae SH, Crown ED, Fredrick LM, Alami NN, Asatryan A, Kim DH, Paik SW, Lee YJ
- KMID: 2522351
- Gut Liver.
- 2021 Nov;15(6):895-903.
- doi: 10.5009/gnl20321
Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea
-
Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B
- KMID: 2522883
- J Korean Med Sci.
- 2021 Nov;36(46):e308.
- doi: 10.3346/jkms.2021.36.e308
Background: Because of the very low incidence of human immunodeficiency virus (HIV) coinfection in Korea, data on hepatitis C virus (HCV)/HIV coinfection are limited. This study aimed to investigate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination
-
Brunner N, Bruggmann P
- KMID: 2518913
- J Prev Med Public Health.
- 2021 Jul;54(4):251-258.
- doi: 10.3961/jpmph.21.151
Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is... -
- CITED
-
- Close
- SHARE
-
- Close
- The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
-
Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J
- KMID: 2517631
- Clin Mol Hepatol.
- 2021 Jul;27(3):474-485.
- doi: 10.3350/cmh.2021.0015
Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
-
Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW
- KMID: 2516253
- J Korean Med Sci.
- 2021 May;36(21):e142.
- doi: 10.3346/jkms.2021.36.e142
Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
-
Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY
- KMID: 2515845
- Gut Liver.
- 2021 May;15(3):410-419.
- doi: 10.5009/gnl20151
Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
-
Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M
- KMID: 2515848
- Gut Liver.
- 2021 May;15(3):440-450.
- doi: 10.5009/gnl19393
Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited... -
- CITED
-
- Close
- SHARE
-
- Close
- The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
-
Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M
- KMID: 2515686
- Korean J Intern Med.
- 2021 May;36(3):544-556.
- doi: 10.3904/kjim.2018.329
Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Results of Liver-related Health Care Checkup in Mongolian Immigrants: A Comparison with Results from Koreans
-
Kim DH, Lee JK, Kim H, Oh Ac, Hong YJ, Park SC, Kong CB
- KMID: 2525789
- Lab Med Online.
- 2021 Apr;11(2):88-92.
- doi: 10.47429/lmo.2021.11.2.88
Background: The incidence and mortality rate of liver cancer in Mongolians are known to be the highest in the world, and liver cancer in Mongolians is mainly caused by chronic... -
- CITED
-
- Close
- SHARE
-
- Close
- Current and future strategies for the treatment of chronic hepatitis C
-
Alshuwaykh O, Kwo PY
- KMID: 2514764
- Clin Mol Hepatol.
- 2021 Apr;27(2):246-256.
- doi: 10.3350/cmh.2020.0230
Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Test Parameters on the Performance of Rapid Anti-Hepatitis C Virus Immunochromatographic Assay
-
Choi EJ, Kim JH, Han MS
- KMID: 2514600
- Lab Med Qual Assur.
- 2021 Mar;43(1):37-42.
- doi: 10.15263/jlmqa.2021.43.1.37
Anti-hepatitis C virus (HCV) immunochromatographic assay (ICA) is commonly used as an early screening test for HCV infection. This study evaluated the influence of test parameters (technician, assay type, kit... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area
-
Shin J, Yu JH, Jin YJ, Lee JW
- KMID: 2514233
- J Liver Cancer.
- 2021 Mar;21(1):34-44.
- doi: 10.17998/jlc.21.1.34
Background/objective: Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) is rarely observed in patients without liver cirrhosis (LC). We evaluated the incidence and clinical feature of HCV-associated HCC patients with or... -
- CITED
-
- Close
- SHARE
-
- Close
- Epidemiological and Clinical History of Viral Hepatitis in Korea
-
Yoon JH, Cho SH, Kim DY, Yu SJ, Han KH
- KMID: 2514846
- Infect Chemother.
- 2021 Mar;53(1):159-165.
- doi: 10.3947/ic.2021.0300
Viral hepatitis is the most important cause of acute and chronic liver disease in Korea. Particularly, hepatitis B virus (HBV) is the leading cause of liver-related mortality. Because of the nationwide... -
- CITED
-
- Close
- SHARE
-
- Close
- Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
-
Chung JW, Choi HY, Ki M, Jang ES, Jeong SH
- KMID: 2513702
- Gut Liver.
- 2021 Mar;15(2):295-306.
- doi: 10.5009/gnl19387
Background/Aims: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI)... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
-
Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH
- KMID: 2513807
- Korean J Intern Med.
- 2021 Mar;36(Suppl 1):S1-S8.
- doi: 10.3904/kjim.2019.357
Background/Aim: This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea. Methods: A total of 242 patients with chronic hepatitis C virus (HCV) genotype... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
-
Kwan BS, Kim JH, Park SJ, Choe WH, Kwon SY, Yoo BC
- KMID: 2513740
- Korean J Intern Med.
- 2021 Mar;36(2):292-304.
- doi: 10.3904/kjim.2019.297
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains... -
- CITED
-
- Close
- SHARE
-
- Close
- A Healthcare-Associated Outbreak of HCV Genotype 2a at a Clinic in Seoul
-
Choi S, Lee H, Lee H, Chung YS
- KMID: 2513221
- Osong Public Health Res Perspect.
- 2021 Feb;12(1):3-12.
- doi: 10.24171/j.phrp.2021.12.1.02
Objectives: An epidemiological investigation was conducted into a hepatitis C virus (HCV) outbreak at an outpatients clinic in Seoul (2011-2012). The aim of the study was to analyze the scale... -
- CITED
-
- Close
- SHARE
-
- Close
- Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals
-
Lee DH, Ryu SH, Myung Hj, Shin YJ, Lee SH, Park TY, Moon JS
- KMID: 2513419
- Korean J Gastroenterol.
- 2021 Feb;77(2):88-91.
- doi: 10.4166/kjg.2020.145
The pegylated interferon plus ribavirin combination therapy has been used as the primary treatment for chronic hepatitis C (CHC) but fails to produce a sustained viral response (SVR) in many... -
- CITED
-
- Close
- SHARE
-
- Close
